{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:26:12Z","timestamp":1789007172750,"version":"build-2803163510"},"reference-count":90,"publisher":"Genomic Press","issue":"1","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,9]]},"abstract":"<jats:p><jats:bold>Classical psychedelics are increasingly receiving attention as potential therapeutic agents for treating post-traumatic stress disorder (PTSD). Research has explored various classical psychedelics in the context of fear learning, recall, and extinction in rodents. We provide an overview of the reported effects of these substances on behavioral responses to learned fear. The amygdala complex, a key brain region involved in fear learning and extinction, plays a central role in these processes. We discuss how psychedelics interact with various cell types in the amygdala and propose which neural circuits may be essential for the observed fear-suppressing effects following psychedelic administration in rodents. The rodent amygdala has functional homology with the human amygdala. Thus, insights gained from preclinical studies can inform the design and implementation of clinical trials for psychedelic-assisted psychotherapy for PTSD. Finally, we stress the importance of considering compound-specific pharmacology and the acute duration of action as key factors in guiding the future direction of this field.<\/jats:bold><\/jats:p>","DOI":"10.61373\/pp024b.0019","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T21:16:31Z","timestamp":1731446191000},"page":"19-24","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the therapeutic potential of psychedelics: Fear extinction mechanisms and amygdala modulation"],"prefix":"10.61373","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-0818","authenticated-orcid":true,"given":"Thomas J.","family":"Kelly","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-song","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"40195","reference":[{"issue":"2","key":"R1","series-title":"Am J Psychiatry","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1176\/appi.ajp.162.2.214","article-title":"A multidimensional meta-analysis of psychotherapy for PTSD","volume":"162","year":"2005","unstructured":"Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry. 2005;162(2):214\u201327. DOI: 10.1176\/appi.ajp.162.2.214. PMID: 15677582"},{"issue":"12","key":"R2","series-title":"Arch Gen Psychiatry","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/archpsyc.1995.03950240066012","article-title":"Posttraumatic stress disorder in the national comorbidity survey","volume":"52","year":"1995","unstructured":"Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry. 1995;52(12):1048\u201360. DOI: 10.1001\/archpsyc.1995.03950240066012. PMID: 7492257"},{"key":"R3","series-title":"Neurosci Biobehav Rev","doi-asserted-by":"publisher","first-page":"104923","DOI":"10.1016\/j.neubiorev.2022.104923","article-title":"How can neurobiology of fear extinction inform treatment?","volume":"143","year":"2022","unstructured":"Craske MG, Sandman CF, Stein MB. How can neurobiology of fear extinction inform treatment? Neurosci Biobehav Rev. 2022;143:104923. DOI: 10.1016\/j.neubiorev.2022.104923. PMID: 36280184"},{"issue":"1","key":"R4","series-title":"Annu Rev Psychol","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev.psych.121208.131631","article-title":"Fear extinction as a model for translational neuroscience: ten years of progress","volume":"63","year":"2012","unstructured":"Milad MR, Quirk GJ. Fear extinction as a model for translational neuroscience: ten years of progress. Annu Rev Psychol. 2012;63(1):129\u201351. DOI: 10.1146\/annurev.psych.121208.131631. PMID: 22129456; PMCID: PMC4942586"},{"key":"R5","series-title":"J Neurol Sci","doi-asserted-by":"publisher","first-page":"120302","DOI":"10.1016\/j.jns.2022.120302","article-title":"Review of potential psychedelic treatments for PTSD","volume":"439","year":"2022","unstructured":"Henner RL, Keshavan MS, Hill KP. Review of potential psychedelic treatments for PTSD. J Neurol Sci. 2022;439:120302. DOI: 10.1016\/j.jns.2022.120302. PMID: 35700643"},{"issue":"10","key":"R6","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","year":"2023","unstructured":"Mitchell JM, Ot'Alora G M, Van Der Kolk B, Shannon S, Bogenschutz M, Gelfand Y,  MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473\u201380. DOI: 10.1038\/s41591-023-02565-4. PMID: 37709999; PMCID: PMC10579091"},{"issue":"6","key":"R7","series-title":"Nat Med","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1176\/appi.focus.23021011","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K,  MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025\u201333. DOI: 10.1176\/appi.focus.23021011. PMID: 37404971; PMCID: PMC10316215"},{"issue":"6","key":"R8","series-title":"Nat Neurosci","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G,  Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26(6):1032\u201341. DOI: 10.1038\/s41593-023-01316-5. PMID: 37280397; PMCID: PMC10244169"},{"issue":"16","key":"R9","series-title":"Neuron","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","year":"2021","unstructured":"Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K,  Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535\u201344.e4. DOI: 10.1016\/j.neuron.2021.06.008. PMID: 34228959; PMCID: PMC8376772"},{"issue":"6633","key":"R10","series-title":"Science","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","article-title":"Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors","volume":"379","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA,  Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379(6633):700\u20136. DOI: 10.1126\/science.adf0435. PMID: 36795823; PMCID: PMC10108900"},{"issue":"1","key":"R11","series-title":"Sci Rep","doi-asserted-by":"publisher","first-page":"14247","DOI":"10.1038\/s41598-019-49913-4","article-title":"Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo","volume":"9","year":"2019","unstructured":"De La Fuente Revenga M, Shin JM, Vohra HZ, Hideshima KS, Schneck M, Poklis JL,  Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo. Sci Rep. 2019;9(1):14247. DOI: 10.1038\/s41598-019-49913-4. PMID: 31582824; PMCID: PMC6776537"},{"issue":"3","key":"R12","series-title":"J Pharmacol Exp Ther","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1124\/jpet.110.172247","article-title":"Interaction of 5-HT2A and 5-HT2C receptors in R(\u2212)-2,5-Dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice","volume":"335","year":"2010","unstructured":"Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC,  Interaction of 5-HT2A and 5-HT2C receptors in R(\u2212)-2,5-Dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther. 2010;335(3):728\u201334. DOI: 10.1124\/jpet.110.172247. PMID: 20858706; PMCID: PMC2993545"},{"key":"R13","series-title":"Neuropharmacology","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","year":"2020","unstructured":"Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology. 2020;167:107933. DOI: 10.1016\/j.neuropharm.2019.107933. PMID: 31917152; PMCID: PMC9191653"},{"issue":"17","key":"R14","series-title":"Neuroreport","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, B\u00e4bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897\u2013902. DOI: 10.1097\/00001756-199812010-00024. PMID: 9875725"},{"issue":"7842","key":"R15","series-title":"Nature","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","year":"2021","unstructured":"Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y,  A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021;589(7842):474\u20139. DOI: 10.1038\/s41586-020-3008-z. PMID: 33299186; PMCID: PMC7874389"},{"issue":"3","key":"R16","series-title":"Cell Rep","doi-asserted-by":"publisher","first-page":"112203","DOI":"10.1016\/j.celrep.2023.112203","article-title":"A non-hallucinogenic LSD analog with therapeutic potential for mood disorders","volume":"42","year":"2023","unstructured":"Lewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB,  A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 2023;42(3):112203. DOI: 10.1016\/j.celrep.2023.112203. PMID: 36884348; PMCID: PMC10112881"},{"issue":"2","key":"R17","series-title":"ACS Pharmacol Transl Sci","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects","volume":"4","year":"2021","unstructured":"Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4(2):563\u20137. DOI: 10.1021\/acsptsci.0c00192. PMID: 33861218; PMCID: PMC8033607"},{"issue":"9","key":"R18","series-title":"Int J Neuropsychopharmacol","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/ijnp\/pyab040","article-title":"A complex impact of systemically administered 5-HT2A receptor ligands on conditioned fear","volume":"24","year":"2021","unstructured":"Hags\u00e4ter SM, Pettersson R, Pettersson C, Atanasovski D, N\u00e4slund J, Eriksson E. A complex impact of systemically administered 5-HT2A receptor ligands on conditioned fear. Int J Neuropsychopharmacol. 2021;24(9):749\u201357. DOI: 10.1093\/ijnp\/pyab040. PMID: 34228806; PMCID: PMC8453278"},{"issue":"7","key":"R19","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41386-022-01324-2","article-title":"Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice","volume":"47","year":"2022","unstructured":"P\u0119dzich BD, Rubens S, Sekssaoui M, Pierre A, Van Schuerbeek A, Marin P,  Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice. Neuropsychopharmacology. 2022;47(7):1304\u201314. DOI: 10.1038\/s41386-022-01324-2. PMID: 35449450; PMCID: PMC9117291"},{"key":"R20","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41386-023-01744-8","article-title":"Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala","volume":"49","year":"2024","unstructured":"Kelly TJ, Bonniwell EM, Mu L, Liu X, Hu Y, Friedman V,  Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala. Neuropsychopharmacology. 2024;49:854\u201363. DOI: 10.1038\/s41386-023-01744-8. PMID: 37752222; PMCID: PMC10948882"},{"key":"R21","series-title":"Br J Pharmacol","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1111\/bph.16315","article-title":"Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT2A and 5-HT1A receptors","volume":"181","year":"2024","unstructured":"Werle I, Nascimento LMM, Dos Santos ALA, Soares LA, Dos Santos RG, Hallak JEC,  Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT2A and 5-HT1A receptors. Br J Pharmacol. 2024;181:1671\u201389. DOI: 10.1111\/bph.16315. PMID: 38320596"},{"issue":"7","key":"R22","series-title":"ACS Chem Neurosci","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1021\/acschemneuro.8b00134","article-title":"Effects of N, N-Dimethyltryptamine on rat behaviors relevant to anxiety and depression","volume":"9","year":"2018","unstructured":"Cameron LP, Benson CJ, Dunlap LE, Olson DE. Effects of N, N-Dimethyltryptamine on rat behaviors relevant to anxiety and depression. ACS Chem Neurosci. 2018;9(7):1582\u201390. DOI: 10.1021\/acschemneuro.8b00134. PMID: 29664276; PMCID: PMC7196340"},{"issue":"24","key":"R23","series-title":"Chin Med J (Engl)","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1097\/CM9.0000000000002647","article-title":"Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity","volume":"136","year":"2023","unstructured":"Du Y, Li Y, Zhao X, Yao Y, Wang B, Zhang L,  Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity. Chin Med J (Engl). 2023;136(24):2983\u201392. DOI: 10.1097\/CM9.0000000000002647. PMID: 37000971; PMCID: PMC10752473"},{"key":"R24","series-title":"Neuropharmacology","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.neuropharm.2012.06.007","article-title":"Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL\/6J mice","volume":"64","year":"2013","unstructured":"Zhang G, \u00c1sgeirsd\u00f3ttir HN, Cohen SJ, Munchow AH, Barrera MP, Stackman RW. Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL\/6J mice. Neuropharmacology. 2013;64:403\u201313. DOI: 10.1016\/j.neuropharm.2012.06.007. PMID: 22722027; PMCID: PMC3477617"},{"issue":"8","key":"R25","series-title":"Eur Neuropsychopharmacol","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26(8):1327\u201337. DOI: 10.1016\/j.euroneuro.2016.05.001. PMID: 27216487"},{"issue":"8","key":"R26","series-title":"Neuropharmacology","first-page":"1083","article-title":"A review of central 5-HT receptors and their function","volume":"38","year":"1999","unstructured":"Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083\u2013152. PMID: 10462127"},{"issue":"3","key":"R27","series-title":"Cell Rep","doi-asserted-by":"publisher","first-page":"109836","DOI":"10.1016\/j.celrep.2021.109836","article-title":"Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice","volume":"37","year":"2021","unstructured":"De La Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z,  Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37(3):109836. DOI: 10.1016\/j.celrep.2021.109836. PMID: 34686347; PMCID: PMC8582597"},{"issue":"19","key":"R28","series-title":"J Med Chem","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1021\/jm060656o","article-title":"1-Aminomethylbenzocycloalkanes:\u2009 conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists","volume":"49","year":"2006","unstructured":"McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE. 1-Aminomethylbenzocycloalkanes:\u2009 conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. J Med Chem. 2006;49(19):5794\u2013803. DOI: 10.1021\/jm060656o. PMID: 16970404"},{"issue":"21","key":"R29","series-title":"ChemMedChem","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1002\/cmdc.202100395","article-title":"25CN-NBOH: a selective agonist for in\u2005vitro and in\u2005vivo investigations of the Serotonin 2A receptor","volume":"16","year":"2021","unstructured":"M\u00e4rcher R\u00f8rsted E, Jensen AA, Kristensen JL. 25CN-NBOH: a selective agonist for in\u2005vitro and in\u2005vivo investigations of the Serotonin 2A receptor. ChemMedChem. 2021;16(21):3263\u201370. DOI: 10.1002\/cmdc.202100395. PMID: 34288515"},{"issue":"5","key":"R30","series-title":"Neurosci Biobehav Rev","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s0149-7634(99)00016-0","article-title":"The neuroanatomical and neurochemical basis of conditioned fear","volume":"23","year":"1999","unstructured":"Fendt M, Fanselow MS. The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev. 1999;23(5):743\u201360. DOI: 10.1016\/s0149-7634(99)00016-0. PMID: 10392663"},{"issue":"2","key":"R31","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/npp.2010.184","article-title":"Dissociable roles of prelimbic and infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear","volume":"36","year":"2011","unstructured":"Sierra-Mercado D, Padilla-Coreano N, Quirk GJ. Dissociable roles of prelimbic and infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear. Neuropsychopharmacology. 2011;36(2):529\u201338. DOI: 10.1038\/npp.2010.184. PMID: 20962768; PMCID: PMC3005957"},{"issue":"1","key":"R32","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/npp.2015.180","article-title":"Stress and fear extinction","volume":"41","year":"2016","unstructured":"Maren S, Holmes A. Stress and fear extinction. Neuropsychopharmacology. 2016;41(1):58\u201379. DOI: 10.1038\/npp.2015.180. PMID: 26105142; PMCID: PMC4677122"},{"issue":"6","key":"R33","series-title":"Nat Rev Neurosci","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrn3945","article-title":"Neuronal circuits for fear and anxiety","volume":"16","year":"2015","unstructured":"Tovote P, Fadok JP, L\u00fcthi A. Neuronal circuits for fear and anxiety. Nat Rev Neurosci. 2015;16(6):317\u201331. DOI: 10.1038\/nrn3945. PMID: 25991441"},{"issue":"2","key":"R34","series-title":"Mol Psychiatry","first-page":"120","article-title":"Mechanisms of fear extinction","volume":"12","year":"2007","unstructured":"Myers KM, Davis M. Mechanisms of fear extinction. Mol Psychiatry. 2007;12(2):120\u201350. PMID: 17160066"},{"key":"R35","series-title":"Front Neurosci","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnins.2010.00036","article-title":"Htr2a Gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice","volume":"4","year":"2010","unstructured":"Weber ET, Andrade R. Htr2a Gene and 5-HT(2A) receptor expression in the cerebral cortex studied using genetically modified mice. Front Neurosci. 2010;4:36. DOI: 10.3389\/fnins.2010.00036. PMID: 20802802; PMCID: PMC2928707"},{"issue":"6","key":"R36","series-title":"Brain Res Bull","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s0361-9230(99)00278-6","article-title":"Cellular localization of serotonin 2A (5HT2A) receptors in the rat brain","volume":"51","year":"2000","unstructured":"Xu T, Pandey SC. Cellular localization of serotonin 2A (5HT2A) receptors in the rat brain. Brain Res Bull. 2000;51(6):499\u2013505. DOI: 10.1016\/s0361-9230(99)00278-6. PMID: 10758340"},{"issue":"1","key":"R37","series-title":"Neuroscience","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.neuroscience.2007.01.047","article-title":"Neuronal localization of 5-HT type 2A receptor immunoreactivity in the rat basolateral amygdala","volume":"146","year":"2007","unstructured":"McDonald AJ, Mascagni F. Neuronal localization of 5-HT type 2A receptor immunoreactivity in the rat basolateral amygdala. Neuroscience. 2007;146(1):306\u201320. DOI: 10.1016\/j.neuroscience.2007.01.047. PMID: 17331657; PMCID: PMC1941573"},{"issue":"3","key":"R38","series-title":"Physiol Rev","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1152\/physrev.00002.2003","article-title":"The amygdaloid complex: anatomy and physiology","volume":"83","year":"2003","unstructured":"Sah P, Faber ESL, Lopez De Armentia M, Power J. The amygdaloid complex: anatomy and physiology. Physiol Rev. 2003;83(3):803\u201334. DOI: 10.1152\/physrev.00002.2003. PMID: 12843409"},{"issue":"5","key":"R39","series-title":"Learn Mem","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1101\/lm.30901","article-title":"Synaptic plasticity in the lateral amygdala: a cellular hypothesis of fear conditioning","volume":"8","year":"2001","unstructured":"Blair HT, Schafe GE, Bauer EP, Rodrigues SM, Ledoux JE. Synaptic plasticity in the lateral amygdala: a cellular hypothesis of fear conditioning. Learn Mem. 2001;8(5):229\u201342. DOI: 10.1101\/lm.30901. PMID: 11584069"},{"issue":"2","key":"R40","series-title":"Brain Res","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0006-8993(92)91303-v","article-title":"Glutamate immunoreactive terminals in the lateral amygdaloid nucleus: a possible substrate for emotional memory","volume":"593","year":"1992","unstructured":"Farb C, Aoki C, Milner T, Kaneko T, Ledoux J. Glutamate immunoreactive terminals in the lateral amygdaloid nucleus: a possible substrate for emotional memory. Brain Res. 1992;593(2):145\u201358. DOI: 10.1016\/0006-8993(92)91303-v. PMID: 1360318"},{"issue":"3","key":"R41","series-title":"Synapse","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/(SICI)1098-2396(19990901)33:3<218::AID-SYN6>3.0.CO;2-1","article-title":"Afferents from rat temporal cortex synapse on lateral amygdala neurons that express NMDA and AMPA receptors","volume":"33","year":"1999","unstructured":"Farb CR, Ledoux JE. Afferents from rat temporal cortex synapse on lateral amygdala neurons that express NMDA and AMPA receptors. Synapse. 1999;33(3):218\u201329. DOI: 10.1002\/(SICI)1098-2396(19990901)33:3<218::AID-SYN6>3.0.CO;2-1. PMID: 10420169"},{"issue":"2\u20133","key":"R42","series-title":"Learn Mem","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1101\/lm.3.2-3.229","article-title":"Convergent but temporally separated inputs to lateral amygdala neurons from the auditory thalamus and auditory cortex use different postsynaptic receptors: in vivo intracellular and extracellular recordings in fear conditioning pathways","volume":"3","year":"1996","unstructured":"Li XF, Stutzmann GE, LeDoux JE. Convergent but temporally separated inputs to lateral amygdala neurons from the auditory thalamus and auditory cortex use different postsynaptic receptors: in vivo intracellular and extracellular recordings in fear conditioning pathways. Learn Mem 1996;3(2\u20133):229\u201342. DOI: 10.1101\/lm.3.2-3.229. PMID: 10456093"},{"issue":"1","key":"R43","series-title":"Neuron","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/s0896-6273(00)80524-3","article-title":"Postsynaptic induction and PKA-dependent expression of LTP in the lateral amygdala","volume":"21","year":"1998","unstructured":"Huang Y-Y, Kandel ER. Postsynaptic induction and PKA-dependent expression of LTP in the lateral amygdala. Neuron. 1998;21(1):169\u201378. DOI: 10.1016\/s0896-6273(00)80524-3. PMID: 9697861"},{"issue":"2","key":"R44","series-title":"J Neurochem","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1471-4159.2008.05461.x","article-title":"Role of AMPA receptor trafficking in NMDA receptor-dependent synaptic plasticity in the rat lateral amygdala","volume":"106","year":"2008","unstructured":"Yu SY, Wu DC, Liu L, Ge Y, Wang YT. Role of AMPA receptor trafficking in NMDA receptor-dependent synaptic plasticity in the rat lateral amygdala. J Neurochem. 2008;106(2):889\u201399. DOI: 10.1111\/j.1471-4159.2008.05461.x. PMID: 18466342"},{"issue":"6277","key":"R45","series-title":"Nature","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/345716a0","article-title":"Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala","volume":"345","year":"1990","unstructured":"Miserendino MJD, Sananes CB, Melia KR, Davis M. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala. Nature. 1990;345(6277):716\u20138. DOI: 10.1038\/345716a0. PMID: 1972778"},{"issue":"1","key":"R46","series-title":"Nat Commun","doi-asserted-by":"publisher","first-page":"8221","DOI":"10.1038\/s41467-023-44016-1","article-title":"Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential","volume":"14","year":"2023","unstructured":"Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM,  Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023;14(1):8221. DOI: 10.1038\/s41467-023-44016-1. PMID: 38102107; PMCID: PMC10724237"},{"issue":"21","key":"R47","series-title":"J Neurosci","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1523\/JNEUROSCI.2700-20.2021","article-title":"Total number and ratio of GABAergic neuron types in the mouse lateral and basal amygdala","volume":"41","year":"2021","unstructured":"Vereczki VK, M\u00fcller K, Krizs\u00e1n \u00c9, M\u00e1t\u00e9 Z, Fekete Z, Rovira-Esteban L,  Total number and ratio of GABAergic neuron types in the mouse lateral and basal amygdala. J Neurosci. 2021;41(21):4575\u201395. DOI: 10.1523\/JNEUROSCI.2700-20.2021. PMID: 33837051; PMCID: PMC8260245"},{"issue":"7991","key":"R48","series-title":"Nature","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41586-023-06808-9","article-title":"Molecularly defined and spatially resolved cell atlas of the whole mouse brain","volume":"624","year":"2023","unstructured":"Zhang M, Pan X, Jung W, Halpern AR, Eichhorn SW, Lei Z,  Molecularly defined and spatially resolved cell atlas of the whole mouse brain. Nature. 2023;624(7991):343\u201354. DOI: 10.1038\/s41586-023-06808-9. PMID: 38092912; PMCID: PMC10719103"},{"issue":"10","key":"R49","series-title":"Biol Psychiatry","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.biopsych.2017.10.006","article-title":"Amygdala inhibitory circuits regulate associative fear conditioning","volume":"83","year":"2018","unstructured":"Krabbe S, Gr\u00fcndemann J, L\u00fcthi A. Amygdala inhibitory circuits regulate associative fear conditioning. Biol Psychiatry. 2018;83(10):800\u20139. DOI: 10.1016\/j.biopsych.2017.10.006. PMID: 29174478"},{"issue":"2","key":"R50","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/npp.2008.71","article-title":"Stress impairs 5-HT2A receptor-mediated serotonergic facilitation of GABA release in juvenile rat basolateral amygdala","volume":"34","year":"2009","unstructured":"Jiang X, Xing G, Yang C, Verma A, Zhang L, Li H. Stress impairs 5-HT2A receptor-mediated serotonergic facilitation of GABA release in juvenile rat basolateral amygdala. Neuropsychopharmacology. 2009;34(2):410\u201323. DOI: 10.1038\/npp.2008.71. PMID: 18536707"},{"key":"R51","series-title":"Brain Res","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.brainres.2010.11.055","article-title":"Distribution of 5-HT2A receptor immunoreactivity in the rat amygdaloid complex and colocalization with \u03b3-aminobutyric acid","volume":"1370","year":"2011","unstructured":"Bombardi C. Distribution of 5-HT2A receptor immunoreactivity in the rat amygdaloid complex and colocalization with \u03b3-aminobutyric acid. Brain Res. 2011;1370:112\u201328. DOI: 10.1016\/j.brainres.2010.11.055. PMID: 21126512"},{"issue":"1","key":"R52","series-title":"Nat Commun","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s41467-022-28928-y","article-title":"Gq neuromodulation of BLA parvalbumin interneurons induces burst firing and mediates fear-associated network and behavioral state transition in mice","volume":"13","year":"2022","unstructured":"Fu X, Teboul E, Weiss GL, Antonoudiou P, Borkar CD, Fadok JP,  Gq neuromodulation of BLA parvalbumin interneurons induces burst firing and mediates fear-associated network and behavioral state transition in mice. Nat Commun. 2022;13(1):1290. DOI: 10.1038\/s41467-022-28928-y. PMID: 35277502; PMCID: PMC8917207"},{"issue":"1","key":"R53","series-title":"J Neurophysiol","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1152\/jn.1999.82.1.69","article-title":"Serotonergic modulation of neurotransmission in the rat basolateral amygdala","volume":"82","year":"1999","unstructured":"Rainnie DG. Serotonergic modulation of neurotransmission in the rat basolateral amygdala. J Neurophysiol. 1999;82(1):69\u201385. DOI: 10.1152\/jn.1999.82.1.69. PMID: 10400936"},{"issue":"12","key":"R54","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/s41386-023-01613-4","article-title":"UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice","volume":"48","year":"2023","unstructured":"Rijsketic DR, Casey AB, Barbosa DAN, Zhang X, Hietamies TM, Ramirez-Ovalle G,  UNRAVELing the synergistic effects of psilocybin and environment on brain-wide immediate early gene expression in mice. Neuropsychopharmacology. 2023;48(12):1798\u2013807. DOI: 10.1038\/s41386-023-01613-4. PMID: 37248402; PMCID: PMC10579391"},{"issue":"9","key":"R55","series-title":"Biol Psychiatry","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.biopsych.2021.12.018","article-title":"Convergent coding of recent and remote fear memory in the basolateral amygdala","volume":"91","year":"2022","unstructured":"Liu J, Totty MS, Melissari L, Bayer H, Maren S. Convergent coding of recent and remote fear memory in the basolateral amygdala. Biol Psychiatry. 2022;91(9):832\u201340. DOI: 10.1016\/j.biopsych.2021.12.018. PMID: 35246314; PMCID: PMC9018498"},{"issue":"11","key":"R56","series-title":"Nat Neurosci","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/nn.4651","article-title":"Cellular and oscillatory substrates of fear extinction learning","volume":"20","year":"2017","unstructured":"Davis P, Zaki Y, Maguire J, Reijmers LG. Cellular and oscillatory substrates of fear extinction learning. Nat Neurosci. 2017;20(11):1624\u201333. DOI: 10.1038\/nn.4651. PMID: 28967909; PMCID: PMC5940487"},{"key":"R57","series-title":"Neuropharmacology","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.neuropharm.2017.10.004","article-title":"TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: a hallucinogenic drug, a selective 5-HT2A receptor pharmacological tool, or none of the above?","volume":"142","year":"2018","unstructured":"Di Giovanni G, De Deurwaerd\u00e8re P. TCB-2 [(7R)-3-bromo-2, 5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine]: a hallucinogenic drug, a selective 5-HT2A receptor pharmacological tool, or none of the above? Neuropharmacology. 2018;142:20\u20139. DOI: 10.1016\/j.neuropharm.2017.10.004. PMID: 28987938"},{"issue":"5","key":"R58","series-title":"Cell","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.cell.2015.10.047","article-title":"Htr2a-expressing cells in the central amygdala control the hierarchy between innate and learned fear","volume":"163","year":"2015","unstructured":"Isosaka T, Matsuo T, Yamaguchi T, Funabiki K, Nakanishi S, Kobayakawa R,  Htr2a-expressing cells in the central amygdala control the hierarchy between innate and learned fear. Cell. 2015;163(5):1153\u201364. DOI: 10.1016\/j.cell.2015.10.047. PMID: 26590419"},{"issue":"1","key":"R59","series-title":"Transl Psychiatry","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41398-023-02414-5","article-title":"Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding","volume":"13","year":"2023","unstructured":"Effinger DP, Quadir SG, Ramage MC, Cone MG, Herman MA. Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. Transl Psychiatry. 2023;13(1):119. DOI: 10.1038\/s41398-023-02414-5. PMID: 37031219; PMCID: PMC10082812"},{"issue":"4","key":"R60","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.pnpbp.2010.02.008","article-title":"Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition","volume":"34","year":"2010","unstructured":"P\u00e1len\u00ed\u010dek T, Hli\u0148\u00e1k Z, Buben\u00edkov\u00e1-Vale\u0161ov\u00e1 V, Nov\u00e1k T, Hor\u00e1\u010dek J. Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(4):588\u201396. DOI: 10.1016\/j.pnpbp.2010.02.008. PMID: 20156516"},{"issue":"4","key":"R61","series-title":"Behav Pharmacol","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/FBP.0000000000000198","article-title":"Sex differences and serotonergic mechanisms in the behavioural effects of psilocin","volume":"27","year":"2016","unstructured":"Tyl\u0161 F, P\u00e1len\u00ed\u010dek T, Kade\u0159\u00e1bek L, Lipski M, Kube\u0161ov\u00e1 A, Hor\u00e1\u010dek J. Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behav Pharmacol. 2016;27(4):309\u201320. DOI: 10.1097\/FBP.0000000000000198. PMID: 26461483"},{"issue":"1","key":"R62","series-title":"Genome Biol","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13059-020-02257-z","article-title":"Evolutionary conservation and divergence of the human brain transcriptome","volume":"22","year":"2021","unstructured":"Pembroke WG, Hartl CL, Geschwind DH. Evolutionary conservation and divergence of the human brain transcriptome. Genome Biol. 2021;22(1):52. DOI: 10.1186\/s13059-020-02257-z. PMID: 33514394; PMCID: PMC7844938"},{"issue":"19","key":"R63","series-title":"J Neurosci","doi-asserted-by":"publisher","first-page":"8696","DOI":"10.1523\/JNEUROSCI.19-19-08696.1999","article-title":"Neurotoxic basolateral amygdala lesions impair learning and memory but not the performance of conditional fear in rats","volume":"19","year":"1999","unstructured":"Maren S. Neurotoxic basolateral amygdala lesions impair learning and memory but not the performance of conditional fear in rats. J Neurosci. 1999;19(19):8696\u2013703. DOI: 10.1523\/JNEUROSCI.19-19-08696.1999. PMID: 10493770; PMCID: PMC6783031"},{"issue":"5","key":"R64","series-title":"Neuron","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/s0896-6273(00)80475-4","article-title":"Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study","volume":"20","year":"1998","unstructured":"LaBar KS, Gatenby JC, Gore JC, LeDoux JE, Phelps EA. Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron. 1998;20(5):937\u201345. DOI: 10.1016\/s0896-6273(00)80475-4. PMID: 9620698"},{"issue":"8","key":"R65","series-title":"Nat Neurosci","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/nn.4324","article-title":"A fast pathway for fear in human amygdala","volume":"19","year":"2016","unstructured":"M\u00e9ndez-B\u00e9rtolo C, Moratti S, Toledano R, Lopez-Sosa F, Mart\u00ednez-Alvarez R, Mah YH,  A fast pathway for fear in human amygdala. Nat Neurosci. 2016;19(8):1041\u20139. DOI: 10.1038\/nn.4324. PMID: 27294508"},{"issue":"6","key":"R66","series-title":"Neuron","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.neuron.2004.08.042","article-title":"Extinction learning in humans","volume":"43","year":"2004","unstructured":"Phelps EA, Delgado MR, Nearing KI, Ledoux JE. Extinction learning in humans. Neuron. 2004;43(6):897\u2013905. DOI: 10.1016\/j.neuron.2004.08.042. PMID: 15363399"},{"issue":"1","key":"R67","series-title":"Curr Biol","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cub.2010.11.042","article-title":"The human amygdala and the induction and experience of fear","volume":"21","year":"2011","unstructured":"Feinstein JS, Adolphs R, Damasio A, Tranel D. The human amygdala and the induction and experience of fear. Curr Biol. 2011;21(1):34\u20138. DOI: 10.1016\/j.cub.2010.11.042. PMID: 21167712; PMCID: PMC3030206"},{"issue":"8","key":"R68","series-title":"Biol Psychiatry","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","article-title":"Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers","volume":"78","year":"2015","unstructured":"Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E,  Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78(8):572\u201381. DOI: 10.1016\/j.biopsych.2014.04.010. PMID: 24882567"},{"key":"R69","series-title":"Biol Psychol","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.biopsycho.2018.01.005","article-title":"Veterans with PTSD demonstrate amygdala hyperactivity while viewing threatening faces: a MEG study","volume":"132","year":"2018","unstructured":"Badura-Brack A, McDermott TJ, Heinrichs-Graham E, Ryan TJ, Khanna MM, Pine DS,  Veterans with PTSD demonstrate amygdala hyperactivity while viewing threatening faces: a MEG study. Biol Psychol. 2018;132:228\u201332. DOI: 10.1016\/j.biopsycho.2018.01.005. PMID: 29309826; PMCID: PMC5801130"},{"issue":"10","key":"R70","series-title":"Am J Psychiatry","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1176\/appi.ajp.2007.07030504","article-title":"Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia","volume":"164","year":"2007","unstructured":"Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164(10):1476\u201388. DOI: 10.1176\/appi.ajp.2007.07030504. PMID: 17898336; PMCID: PMC3318959"},{"issue":"5","key":"R71","series-title":"BMJ Open","doi-asserted-by":"publisher","first-page":"e068884","DOI":"10.1136\/bmjopen-2022-068884","article-title":"Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD","volume":"13","year":"2023","unstructured":"Davis AK, Levin AW, Nagib PB, Armstrong SB, Lancelotta RL. Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ Open. 2023;13(5):e068884. DOI: 10.1136\/bmjopen-2022-068884. PMID: 37142308; PMCID: PMC10163450"},{"issue":"1","key":"R72","series-title":"J Psychopharmacol","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/02698811211066709","article-title":"Validation of the psychological insight scale: a new scale to assess psychological insight following a psychedelic experience","volume":"36","year":"2022","unstructured":"Peill JM, Trinci KE, Kettner H, Mertens LJ, Roseman L, Timmermann C,  Validation of the psychological insight scale: a new scale to assess psychological insight following a psychedelic experience. J Psychopharmacol. 2022;36(1):31\u201345. DOI: 10.1177\/02698811211066709. PMID: 34983255; PMCID: PMC8801624"},{"issue":"7","key":"R73","series-title":"J Psychopharmacol","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/02698811231158245","article-title":"Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: findings from the global drug survey 2020","volume":"37","year":"2023","unstructured":"Kopra EI, Ferris JA, Winstock AR, Kuypers KP, Young AH, Rucker JJ. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: findings from the global drug survey 2020. J Psychopharmacol. 2023;37(7):733\u201348. DOI: 10.1177\/02698811231158245. PMID: 36876583; PMCID: PMC10350727"},{"issue":"7","key":"R74","series-title":"Neurosci Biobehav Rev","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.neubiorev.2008.03.006","article-title":"Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease","volume":"32","year":"2008","unstructured":"Holmes A. Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev. 2008;32(7):1293\u2013314. DOI: 10.1016\/j.neubiorev.2008.03.006. PMID: 18439676; PMCID: PMC2561331"},{"key":"R75","series-title":"Nature","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41586-024-07403-2","article-title":"Structural pharmacology and therapeutic potential of 5-methoxytryptamines","volume":"630","year":"2024","unstructured":"Warren AL, Lankri D, Cunningham MJ, Serrano IC, Parise LF, Kruegel AC,  Structural pharmacology and therapeutic potential of 5-methoxytryptamines. Nature. 2024;630:237\u201346. DOI: 10.1038\/s41586-024-07403-2. PMID: 38720072; PMCID: PMC11152992"},{"issue":"24","key":"R76","series-title":"Proc Natl Acad Sci","doi-asserted-by":"publisher","first-page":"14476","DOI":"10.1073\/pnas.95.24.14476","article-title":"Serotonin receptor 1A knockout: an animal model of anxiety-related disorder","volume":"95","year":"1998","unstructured":"Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M,  Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci. 1998;95(24):14476\u201381. DOI: 10.1073\/pnas.95.24.14476. PMID: 9826725; PMCID: PMC24398"},{"issue":"12","key":"R77","series-title":"Biol Psychiatry","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/s0006-3223(00)01041-6","article-title":"Altered fear circuits in 5-HT1A receptor KO mice","volume":"48","year":"2000","unstructured":"Gross C, Santarelli L, Brunner D, Zhuang X, Hen R. Altered fear circuits in 5-HT1A receptor KO mice. Biol Psychiatry. 2000;48(12):1157\u201363. DOI: 10.1016\/s0006-3223(00)01041-6. PMID: 11137057"},{"issue":"1","key":"R78","series-title":"Neuropsychopharmacology","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/sj.npp.1300774","article-title":"Increased fear response to contextual cues in mice lacking the 5-HT1A receptor","volume":"31","year":"2006","unstructured":"Klemenhagen KC, Gordon JA, David DJ, Hen R, Gross CT. Increased fear response to contextual cues in mice lacking the 5-HT1A receptor. Neuropsychopharmacology. 2006;31(1):101\u201311. DOI: 10.1038\/sj.npp.1300774. PMID: 15920501"},{"issue":"1\u20132","key":"R79","series-title":"Eur J Pharmacol","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejphar.2005.12.008","article-title":"5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala","volume":"532","year":"2006","unstructured":"Li X, Inoue T, Abekawa T, Weng S, Nakagawa S, Izumi T,  5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala. Eur J Pharmacol. 2006;532(1\u20132):74\u201380. DOI: 10.1016\/j.ejphar.2005.12.008. PMID: 16460727"},{"issue":"Suppl","key":"R80","series-title":"J Clin Psychiatry","first-page":"3","article-title":"Buspirone in the long-term treatment of generalized anxiety disorder","volume":"48","year":"1987","unstructured":"Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry. 1987;48 Suppl:3\u20136. PMID: 3320034"},{"key":"R81","series-title":"Front Psychiatry","doi-asserted-by":"publisher","first-page":"1271152","DOI":"10.3389\/fpsyt.2023.1271152","article-title":"5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study","volume":"14","year":"2023","unstructured":"Ragnhildstveit A, Khan R, Seli P, Bass LC, August RJ, Kaiyo M,  5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study. Front Psychiatry. 2023;14:1271152. DOI: 10.3389\/fpsyt.2023.1271152. PMID: 38076677; PMCID: PMC10710141"},{"issue":"5","key":"R82","series-title":"Am J Drug Alcohol Abuse","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/00952990.2023.2220874","article-title":"Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male special operations forces veterans: prospective data from a clinical program in Mexico","volume":"49","year":"2023","unstructured":"Davis AK, Xin Y, Sepeda N, Averill LA. Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male special operations forces veterans: prospective data from a clinical program in Mexico. Am J Drug Alcohol Abuse. 2023;49(5):587\u201396. DOI: 10.1080\/00952990.2023.2220874. PMID: 37734158"},{"issue":"9","key":"R83","series-title":"Psychopharmacology (Berl)","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s00213-019-05236-w","article-title":"A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psyc","volume":"236","year":"2019","unstructured":"Uthaug MV, Lancelotta R, Van Oorsouw K, Kuypers KPC, Mason N, Rak J,  A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psyc. Psychopharmacology (Berl). 2019;236(9):2653\u201366. DOI: 10.1007\/s00213-019-05236-w. PMID: 30982127; PMCID: PMC6695371"},{"issue":"7","key":"R84","series-title":"J Psychopharmacol","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1177\/0269881118769063","article-title":"The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption","volume":"32","year":"2018","unstructured":"Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E. The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol. 2018;32(7):779\u201392. DOI: 10.1177\/0269881118769063. PMID: 29708042; PMCID: PMC6248886"},{"issue":"2","key":"R85","series-title":"J Psychedelic Stud","first-page":"104","article-title":"A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting","volume":"4","year":"2020","unstructured":"Uthaug MV, Lancelotta R, Ortiz Bernal AM, Davis AK, Ramaekers JG. A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. J Psychedelic Stud. 2020;4(2):104\u201313."},{"issue":"6","key":"R86","series-title":"Psychopharmacology (Berl)","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00213-021-06049-6","article-title":"Assessing the risk\u2013benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research","volume":"239","year":"2022","unstructured":"Bender D, Hellerstein DJ. Assessing the risk\u2013benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology (Berl). 2022;239(6):1907\u201332. DOI: 10.1007\/s00213-021-06049-6. PMID: 35022823"},{"issue":"6","key":"R87","series-title":"J Psychopharmacol","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320. DOI: 10.1177\/0269881108093587. PMID: 18593734; PMCID: PMC3056407"},{"issue":"2","key":"R88","series-title":"Pharmacol Ther","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease\u2014it was meant 2B","volume":"132","year":"2011","unstructured":"Hutcheson JD, Setola V, Roth BL, Merryman WD. Serotonin receptors and heart valve disease\u2014it was meant 2B. Pharmacol Ther. 2011;132(2):146\u201357. DOI: 10.1016\/j.pharmthera.2011.03.008. PMID: 21440001; PMCID: PMC3179857"},{"issue":"10","key":"R89","series-title":"Expert Opin Drug Saf","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/14740338.2023.2248883","article-title":"Serotonin 5-HT(2B) receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents","volume":"22","year":"2023","unstructured":"McIntyre RS. Serotonin 5-HT(2B) receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents. Expert Opin Drug Saf. 2023;22(10):881\u20133. DOI: 10.1080\/14740338.2023.2248883. PMID: 37581427"},{"issue":"9","key":"R90","series-title":"Am J Cardiol","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.amjcard.2007.06.045","article-title":"Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease","volume":"100","year":"2007","unstructured":"Droogmans S, Cosyns B, D'Haenen H, Creeten E, Weytjens C, Franken PR,  Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. Am J Cardiol. 2007;100(9):1442\u20135. DOI: 10.1016\/j.amjcard.2007.06.045. PMID: 17950805"}],"container-title":["Psychedelics"],"original-title":[],"link":[{"URL":"https:\/\/genomicpress.kglmeridian.com\/view\/journals\/psychedelics\/1\/1\/article-p19.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/genomicpress.kglmeridian.com\/downloadpdf\/journals\/psychedelics\/1\/1\/article-p19.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/genomicpress.kglmeridian.com\/downloadpdf\/journals\/psychedelics\/1\/1\/article-p19.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T13:57:12Z","timestamp":1745503032000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomicpress.kglmeridian.com\/view\/journals\/psychedelics\/1\/1\/article-p19.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":90,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.61373\/pp024b.0019","relation":{},"ISSN":["2997-268X","2997-2671"],"issn-type":[{"value":"2997-268X","type":"print"},{"value":"2997-2671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]}}}